ReviewFrontiers in immunology2014
Regulatory T cells as immunotherapy.
Review in Frontiers in immunology, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 112 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
112 citing papers in PubMed, 182 citations in OpenAlex.
- Clinical Evolution, Outcomes, and Emerging Preservation Technologies in Pancreas and Islet Transplantation.Journal of clinical medicine · 2026Review
- Maintenance DNA methylation is necessary for age-related alterations in regulatory T cell transcriptional and DNA methylation signatures.bioRxiv : the preprint server for biology · 2026Article
- DC-CD4 bispecific tolerogenic nanovesicles induce antigen-specific regulatory T cells and ameliorate collagen-induced arthritis in mice.Nature communications · 2026Article
- From stasis to systematics: deciphering the pathophysiology of secondary lymphedema through omics.Frontiers in immunology · 2026Review
- FOXP3+ T Cells-An Emerging Evidence in Periodontitis Therapeutics.Clinical and experimental dental research · 2025Review
- Therapeutic potential of S-nitrosoglutathione reductase inhibitor in B cell-driven experimental autoimmune encephalomyelitis.Journal of neuroimmunology · 2025Article
- Article
- The role of S-nitrosoglutathione reductase (GSNOR) in T cell-mediated immunopathology of experimental autoimmune encephalomyelitis (EAE).Neuroscience · 2025Article
- The role, relevance and management of immune exhaustion in bovine infectious diseases.Heliyon · 2024Review
- Microneedle-Mediated Cell Therapy.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2024Review
- Regulatory T cell homing and activation is a signature of neonatal sepsis.Frontiers in immunology · 2024Article
- Immune regulation and therapeutic application of T regulatory cells in liver diseases.Frontiers in immunology · 2024Review
- A novel inducible haematopoietic cell-depleting mouse model for chimeric complementation of blood cells.Cell proliferation · 2023Article
- Advances in dendritic cell targeting nano-delivery systems for induction of immune tolerance.Frontiers in bioengineering and biotechnology · 2023Review
- Tolerogenic nanoparticles induce type II collagen-specific regulatory T cells and ameliorate osteoarthritis.Science advances · 2022Article
- TNFR2 antagonist and agonist: a potential therapeutics in cancer immunotherapy.Medical oncology (Northwood, London, England) · 2022Review
- Advancing Lung Immunology Research: An Official American Thoracic Society Workshop Report.American journal of respiratory cell and molecular biology · 2022Article
- Typical and atypical properties of peripheral nerve allografts enable novel strategies to repair segmental-loss injuries.Journal of neuroinflammation · 2022Review
- Epigenetic Control of Regulatory T Cell Stability and Function: Implications for Translation.Frontiers in immunology · 2022Review
- CXCR4 blockade reduces the severity of murine heart allograft rejection by plasmacytoid dendritic cell-mediated immune regulation.Scientific reports · 2021Article
52 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 1 institution in 1 country.
Funding
Abstract
Regulatory T cells (Tregs) suppress exuberant immune system activation and promote immunologic tolerance. Because Tregs modulate both innate and adaptive immunity, the biomedical community has developed an intense interest in using Tregs for immunotherapy. Conditions that require clinical tolerance to improve outcomes - autoimmune disease, solid organ transplantation, and hematopoietic stem cell transplantation - may benefit from Treg immunotherapy. Investigators have designed ex vivo strategies to isolate, preserve, expand, and infuse Tregs. Protocols to manipulate Treg populations in vivo have also been considered. Barriers to clinically feasible Treg immunotherapy include Treg stability, off-cell effects, and demonstration of cell preparation purity and potency. Clinical trials involving Treg adoptive transfer to treat graft versus host disease preliminarily demonstrated the safety and efficacy of Treg immunotherapy in humans. Future work will need to confirm the safety of Treg immunotherapy and establish the efficacy of specific Treg subsets for the treatment of immune-mediated disease.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.